Sitagliptin + placebo

ApprovedCompleted

0 views this week 0 watching⚡ Active

Interest: 43/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

✓

Phase 3

Approved

Indication / Disease

Neoplasms, Adipose Tissue

Conditions

Neoplasms, Adipose Tissue

Trial Timeline

Mar 1, 2014 → Dec 1, 2016

NCT ID

NCT02294084

About Sitagliptin + placebo

Sitagliptin + placebo is a approved stage product being developed by Merck for Neoplasms, Adipose Tissue. The current trial status is completed. This product is registered under clinical trial identifier NCT02294084. Target conditions include Neoplasms, Adipose Tissue.

What happened to similar drugs?

20 of 20 similar drugs in Neoplasms, Adipose Tissue were approved

Approved (20) Terminated (2) Active (0)

✅LenvatinibEisaiApproved

✅Eribulin mesylateEisaiApproved

✅Eribulin MesylateEisaiApproved

✅Abemaciclib + Nonsteroidal Aromatase Inhibitor (NSAI) + FulvestrantEli LillyApproved

✅Chlorhydrate de RopivacaineAstraZenecaApproved

✅Palonosetron and DexamethasoneMerckApproved

✅Pegylated Liposomal Doxorubicin hydrochlorideMerckApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (13)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02536248	Phase 3	Completed	Aug 1, 2015	Oct 31, 2017	Type 2 Diabetes Mellitus
NCT02256189	Approved	Completed	Apr 1, 2015	Jun 1, 2017	Type 2 Diabetes
NCT02294084	Approved	Completed	Mar 1, 2014	Dec 1, 2016	Neoplasms, Adipose Tissue
NCT02015910	Approved	Terminated	Jan 1, 2014	Jan 1, 2015	Type II Diabetes
NCT01928199	Approved	Completed	Sep 1, 2013	Oct 1, 2020	Posttransplant Diabetes Mellitus
NCT01859793	Approved	Completed	Jun 1, 2013	Jul 1, 2016	Diabetes
NCT01600703	Phase 2/3	Completed	Jul 1, 2012	Aug 1, 2013	Hyperlipidemia
NCT01334229	Phase 3	Completed	Apr 1, 2011	Dec 1, 2013	Type 2 Diabetes Mellitus
NCT01272583	Pre-clinical	Completed	Mar 1, 2011	Oct 1, 2012	Type 1 Diabetes
NCT00790205	Phase 3	Completed	Dec 10, 2008	Mar 30, 2015	Type 2 Diabetes Mellitus
NCT00732121	Approved	UNKNOWN	Aug 1, 2008	Aug 1, 2010	Type 2 Diabetes
NCT00660075	Phase 3	Completed	Feb 1, 2008	Apr 1, 2009	Diabetes Mellitus
NCT00501657	Phase 1	Completed	Jul 1, 2007	Dec 1, 2011	Gastroparesis

Competing Products

20 competing products in Neoplasms, Adipose Tissue

See all competitors

Product	Company	Stage	Hype Score
ADC-1013	Alligator Bioscience AB	Phase 1	19
AB0024	Gilead Sciences	Phase 1	29
TTI-237	Pfizer	Phase 1	21
852A	Pfizer	Phase 1	29
Pemetrexed	Eli Lilly	Phase 2	35
IMC-3C5	Eli Lilly	Phase 1	29
LY3295668	Eli Lilly	Phase 1/2	32
Galunisertib + Gemcitabine + Placebo	Eli Lilly	Phase 1/2	32
Fulvestrant + Abemaciclib	Eli Lilly	Phase 2	39
Abemaciclib + Fulvestrant + Placebo	Eli Lilly	Phase 3	44
LY2784544	Eli Lilly	Phase 1	29
enzastaurin	Eli Lilly	Phase 2	35
Abemaciclib + Darolutamide + LHRH agonist/antagonist	Eli Lilly	Phase 1	29
Gemcitabine + liposomal doxorubicin	Eli Lilly	Phase 3	40
120 mg LY2784544	Eli Lilly	Phase 2	39
LY4337713	Eli Lilly	Phase 1	36
pemetrexed + cisplatin	Eli Lilly	Phase 1/2	32
LY4064809 + Placebo + Ribociclib + Palbociclib + Abemaciclib + Anastrozole + Letrozole + Exemestane + Fulvestrant	Eli Lilly	Phase 3	47
VIP152 (BAY 1251152) + VIP152 (BAY 1251152) 30 mg + Keytruda + VIP152 (BAY 1251152) 15 mg	Vincerx Pharma	Phase 1	19
VIP236 (Q3W) + VIP236 (Q2W)	Vincerx Pharma	Phase 1	19